Verona Pharma Plc ADR (VRNA) concluded trading on Wednesday at a closing price of $104.77, with 65.64 million shares of worth about $6.88 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 124.88% during that period and on July 09, 2025 the price saw a gain of about 20.62%. Currently the company’s common shares owned by public are about 85.13M shares, out of which, 76.73M shares are available for trading.
Stock saw a price change of 15.79% in past 5 days and over the past one month there was a price change of 24.22%. Year-to-date (YTD), VRNA shares are showing a performance of 550.34% which increased to 125.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $16.61 but also hit the highest price of $99.01 during that period. The average intraday trading volume for Verona Pharma Plc ADR shares is 1.32 million. The stock is currently trading 12.69% above its 20-day simple moving average (SMA20), while that difference is up 28.16% for SMA50 and it goes to 84.30% higher than SMA200.
Verona Pharma Plc ADR (NASDAQ: VRNA) currently have 85.13M outstanding shares and institutions hold larger chunk of about 76.31% of that.
The stock has a current market capitalization of $8.92B and its 3Y-monthly beta is at 0.12. It has posted earnings per share of -$2.04 in the same period. It has Quick Ratio of 8.73 while making debt-to-equity ratio of 1.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VRNA, volatility over the week remained 3.41% while standing at 3.60% over the month.
Analysts are in expectations that Verona Pharma Plc ADR (VRNA) stock would likely to be making an EPS of 0.39 in the current quarter, while forecast for next quarter EPS is 0.48 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.39 which is 0.39 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 165.66% while it is estimated to increase by 749.23% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on July 01, 2025 offering an Outperform rating for the stock and assigned a target price of $170 to it. Coverage by TD Cowen stated Verona Pharma Plc ADR (VRNA) stock as a Buy in their note to investors on April 28, 2025, suggesting a price target of $100 for the stock. On April 21, 2025, Cantor Fitzgerald Initiated their recommendations, while on January 10, 2025, ROTH MKM Initiated their ratings for the stock with a price target of $68. Stock get an Overweight rating from Wells Fargo on October 03, 2024.
